Neostigmin Sad (Neostigmine Bromide)

Neostigmine inhibits the enzyme acetylcholinesterase, which normally breaks down acetylcholine. By blocking this enzyme, acetylcholine accumulates at synapses, enhancing cholinergic transmission. This results in improved muscle contraction in myasthenia gravis, reversal of muscle relaxation after anesthesia, and increased gastrointestinal motility.

The specific dose of Neostigmin Sad is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and route of administration. Healthcare professionals calculate the appropriate amount and frequency according to established clinical guidelines.

The safety of neostigmine during pregnancy and lactation has not been definitively established, and the product is classified as pregnancy category unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Neostigmine is an anticholinesterase that reverses non‑depolarizing neuromuscular blockers, whereas newer agents like sugammadex encapsulate specific blockers (e.g., rocuronium). Neostigmine is less expensive and widely available but may cause cholinergic side effects, requiring co‑administration of antimuscarinic agents.

Neostigmin Sad should be stored at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture, direct sunlight, and extreme temperatures to maintain stability and potency.

Neostigmin Sad is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously. The route and rate of administration are selected by the treating clinician according to the indication and patient response.

Serious risks include bradycardia, severe hypotension, bronchospasm, cholinergic crisis leading to muscle weakness, and seizures. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after administration.

Neostigmin Sad is contraindicated in patients with known hypersensitivity to neostigmine or any excipients, and it should be used with caution in individuals with severe asthma, chronic obstructive pulmonary disease, or significant cardiac conduction abnormalities.